Shawn Rose
Vermogen: - $ op 31-05-2026
Vermogen: - $ op 31-05-2026
Shawn Rose currently works at Nkarta, Inc., as Chief Medical Officer, Head-Research & Development from 2025.
Dr. Rose also formerly worked at Vividion Therapeutics, Inc., as Chief Development Officer-Immunology and Magenta Therapeutics, Inc., as Senior Vice President & Head-Clinical Development.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
NKARTA, INC. -.--% | 17-04-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| NKARTA, INC. | Hoofd Techniek/Wetenschap/O&O | 23-06-2025 |
| Bedrijven | Functie | Einde |
|---|---|---|
| MAGENTA THERAPEUTICS | Hoofd Techniek/Wetenschap/O&O | 07-02-2023 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 3 |
|---|---|
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Health Technology |
Magenta Therapeutics, Inc.
Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures novel medicines | Health Technology |
Nkarta, Inc.
Nkarta, Inc. BiotechnologyHealth Technology Discovers, develops and delivers NK cell therapies for cancer treatment | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau